Checkpoint Inhibitor, Immune

DRUG4 trials

Conditions

Advanced or Metastatic Solid TumorsCancerChondrosarcomaHepatocellular CancerHepatocellular CarcinomaHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma RecurrentLiver Cancer

Phase 1

A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

TerminatedNCT05497453

Omega TherapeuticsHepatocellular Cancer, Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable +4

Start: 2022-08-19End: 2024-11-21Updated: 2025-02-03

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

TerminatedNCT05716295

Medikine, Inc.Advanced or Metastatic Solid Tumors

Start: 2023-02-08End: 2024-04-30Updated: 2024-05-08

Phase 2

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Active, not recruitingNCT04673942

EpicentRx, Inc.Cancer, Chondrosarcoma, Neoplasms +3

Start: 2021-03-29End: 2027-03-01Target: 140Updated: 2026-06-26

Unknown Phase

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

RecruitingNCT05037825

VastBiomeMalignant Melanoma, Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma +1

Start: 2021-11-22End: 2028-09-14Target: 800Updated: 2022-04-27

Journal of Clinical Oncology2025-05-28

First-in-human phase 1/2 study (MYCHELANGELO I) of first-in-class epigenomic controller OTX-2002 targeting MYC oncogene in patients with hepatocellular carcinoma (HCC) and other solid tumors.

Journal of Clinical Oncology2025-01-272 citations

TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.

2024-10-261 citations

Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.

Journal of Clinical Oncology2024-06-012 citations

Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing

Journal for ImmunoTherapy of Cancer2024-06-01

Abstract 2417: Detection and quantification of site-specific DNA methylation from liquid biopsies as a pharmacodynamic biomarker of OTX-2002, a novel MYC-targeting epigenomic mRNA therapeutic

Cancer Research2024-03-221 citations

1523 AdAPT-001 in advanced soft-tissue sarcoma (BETA PRIME): a multicenter, open-label, phase 1 clinical trial

2023-10-31

TGF-β: The Apex Predator of Immune Checkpoints

Future Oncology2023-07-284 citations

Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001<sup>TGF-ß Trap</sup>.

Journal of Clinical Oncology2023-06-014 citations

A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).

Journal of Clinical Oncology2023-01-249 citations

Checkpoint Inhibitor, Immune

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers